These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 9551574

  • 1. [Antihypertensive therapy with doxazosin in patients with non-insulin-dependent diabetes mellitus].
    Lazebnik LB, Melichenko SB, Serebrov AN.
    Ter Arkh; 1998; 70(2):50-4. PubMed ID: 9551574
    [Abstract] [Full Text] [Related]

  • 2. [Tonocardin in complex treatment of diabetes mellitus concurrent with hypertension].
    Balabolkin MI, Khasanova ER, Trukhina TV, Kreminskaia VM.
    Ter Arkh; 2002; 74(12):38-41. PubMed ID: 12577838
    [Abstract] [Full Text] [Related]

  • 3. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, Muggeo M.
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [Abstract] [Full Text] [Related]

  • 4. Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
    Feher MD, Henderson AD, Wadsworth J, Poulter C, Gelding S, Richmond W, Sever PS, Elkeles RS.
    J Hum Hypertens; 1990 Oct; 4(5):571-7. PubMed ID: 1980930
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of slow release urapidil (ebrantil) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM).
    Oren S, Turkot S, Paran E, Flandra O, Slezak L, Hof B.
    J Hum Hypertens; 1996 Feb; 10(2):123-7. PubMed ID: 8867567
    [Abstract] [Full Text] [Related]

  • 6. The bedtime administration of doxazosin controls morning hypertension and albuminuria in patients with type-2 diabetes: evaluation using home-based blood pressure measurements.
    Kamoi K, Ikarashi T.
    Clin Exp Hypertens; 2005 May; 27(4):369-76. PubMed ID: 15921073
    [Abstract] [Full Text] [Related]

  • 7. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y, Tsuchihashi T, Onaka U, Eto K, Ueno M.
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [Abstract] [Full Text] [Related]

  • 8. [Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
    Hoogenberg K, van der Tuin J.
    Ned Tijdschr Geneeskd; 2002 Nov 02; 146(44):2099-100. PubMed ID: 12448967
    [Abstract] [Full Text] [Related]

  • 9. Antihypertensive and metabolic effects of doxazosin in hypertensive patients with concomitant non-insulin-dependent diabetes mellitus.
    Inoue Y, Kaku K, Kaneko T, Matsumura S, Nakayama H, Yoshizaki Y, Ando S, Inoue M, Hatao M.
    J Int Med Res; 1996 Nov 02; 24(1):138-46. PubMed ID: 8674792
    [Abstract] [Full Text] [Related]

  • 10. [An AT-II blocker in patients with type II diabetes and arterial hypertension].
    Ametov AS, Demidova TIu, Kosykh SA.
    Klin Med (Mosk); 2006 Nov 02; 84(2):50-5. PubMed ID: 16613007
    [Abstract] [Full Text] [Related]

  • 11. Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy.
    Ikeda T, Gomi T, Shibuya Y, Shinozaki S, Suzuki Y, Matsuda N.
    Hypertens Res; 2007 Nov 02; 30(11):1097-105. PubMed ID: 18250559
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial.
    Chapman N, Chang CL, Dahlöf B, Sever PS, Wedel H, Poulter NR, ASCOT Investigators.
    Circulation; 2008 Jul 01; 118(1):42-8. PubMed ID: 18559700
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.